文献速递肝胆胰外科围术期管理与 ERAS

糖皮质激素对肝胆胰手术后结局的影响

Impact of corticosteroids on postoperative outcomes after hepatopancreatobiliary surgery.
PubMed 文献 · Surgery · 2025-12-02

基于Epic Cosmos数据库2016-2024年125,269例肝胆胰手术(排除单纯胆囊切除)患者的真实世界研究显示,手术当日接受单次糖皮质激素(甲泼尼龙或氢化可的松)者占2.2%;经稳定逆概率治疗加权调整后,激素使用与术后并发症、延长住院及90天死亡率升高相关,提示肝胆胰围术期不应常规使用糖皮质激素。

要点

  • 肝胆胰手术当日使用糖皮质激素与术后并发症风险升高相关(OR 2.16)。
  • 激素使用与延长住院(OR 1.56)及90天死亡率(OR 1.26)升高相关。
  • 亚组分析中激素未显著影响胆漏或胰瘘发生率。

核心结论

  • 基于真实世界电子健康记录数据,肝胆胰手术围术期使用糖皮质激素未改善术后结局,反而对术后结局有不利影响,提示不应常规使用。

研究设计与样本

  • 回顾性队列研究,使用Epic Cosmos数据库纳入2016至2024年接受肝胆胰手术(排除单纯胆囊切除)的患者125,269例。
  • 主要暴露为手术当日单次给予糖皮质激素(甲泼尼龙或氢化可的松),采用稳定逆概率治疗加权分析其与术后结局的关联。

主要发现

  • 125,269例中多数为胰腺手术(n=65,663,52.4%),非恶性肿瘤指征者占63.2%(n=79,145)。
  • 手术当日接受糖皮质激素者占2.2%(n=2,782)。
  • 接受激素者更年轻(61.9岁[标准差±14.7] vs 63.8岁[标准差±14.8])、Charlson合并症指数>2比例更高(79.5% vs 72.2%)、肝脏手术比例更高(42.7% vs 31.0%)、开放手术比例更高(93.4% vs 86.5%)、非恶性肿瘤指征比例更高(72.9% vs 63.0%)(均P<.05)。
  • 逆概率治疗加权调整后,激素使用与术后并发症(OR 2.16[95%CI 1.93-2.42])、延长住院(>第75百分位)(OR 1.56[95%CI 1.40-1.73])及90天死亡率(OR 1.26[95%CI 1.11-1.41])升高相关(均P<.001)。
  • 亚组分析中,激素未影响肝胆手术患者胆漏发生率(OR 1.15[95%CI 0.92-1.43]),也未影响胰腺手术患者胰瘘发生率(OR 1.11[95%CI 0.83-1.47])(均P>.05)。

临床怎么用

  • 肝胆胰手术围术期不应常规使用糖皮质激素以改善术后结局。
  • 对拟用激素者需权衡其与并发症、住院延长及90天死亡率升高的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phase 3 clinical trial data have suggested that perioperative administration of corticosteroids may improve postoperative outcomes by suppressing inflammatory and immune responses associated with surgery. We sought to investigate the real-world effectiveness of corticosteroid administration to improve postoperative outcomes among patients undergoing hepatopancreatobiliary surgery. METHODS: Patients who underwent hepatopancreatobiliary surgery (excluding simple cholecystectomy) between 2016 and 2024 were identified using the Epic Cosmos database. The primary exposure was the administration of a single shot of corticosteroids (methylprednisolone or hydrocortisone) on the day of surgery. Stabilized inverse probability of treatment weighting was used to examine the association between administration of corticosteroids and postoperative outcomes (ie, complications, length of stay, and 90-day mortality). RESULTS: Among 125,269 patients, a majority underwent pancreatic surgery (n = 65,663, 52.4%) for a nonmalignant indication (n = 79,145, 63.2%). Overall, 2.2% of patients (n = 2,782) were administered corticosteroids on the day of surgery. Patients who did versus did not receive corticosteroids were more likely to be younger (61.9 years [standard deviation ±14.7 years] vs 63.8 years [standard deviation ±14.8 years]), have a higher Charlson Comorbidity Index (>2) (79.5% vs 72.2%), and undergo hepatic surgery (42.7% vs 31.0%) via an open surgical approach (93.4% vs 86.5%) for a nonmalignant indication (72.9% vs 63.0%) (all P < .05). On inverse probability of treatment weighting analysis after adjusting for relevant clinicodemographic factors, administration of corticosteroids was associated with higher odds of postoperative complications (odds ratio: 2.16 [95% confidence interval: 1.93-2.42]), extended length of stay (>75th percentile) (odds ratio: 1.56 [95% confidence interval: 1.40-1.73]), and 90-day mortality (odds ratio: 1.26 [95% confidence interval: 1.11-1.41]) (all P < .001). On subgroup analyses, the administration of corticosteroids did not impact the incidence of bile leak among patients undergoing hepatobiliary surgery (odds ratio: 1.15 [95% confidence interval: 0.92-1.43]), nor did it affect the incidence of pancreatic fistula among patients undergoing pancreatic surgery (odds ratio: 1.11 [95% confidence interval: 0.83-1.47]) (both P > .05). CONCLUSION: Based on real-world electronic health record data, administration of corticosteroids was not associated with improved outcomes after a hepatopancreatobiliary surgical procedure. Rather, use of same-day corticosteroids had a detrimental effect on postoperative outcomes, suggesting that steroids should not be routinely used in the perioperative hepatopancreatobiliary setting.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Altaf A, Woldesenbet S, Tong K, et al. Impact of corticosteroids on postoperative outcomes after hepatopancreatobiliary surgery. Surgery. 2025. PMID: 41339208. doi:10.1016/j.surg.2025.109916

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。